|
業務類別
|
Biotechnology |
|
業務概覽
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), andEPX-200 (lorcaserin), among others. |
| 公司地址
| 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462 |
| 電話號碼
| +1 484 539-9800 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.harmonybiosciences.com |
| 員工數量
| 293 |
| Dr. Jeffrey M. Dayno, M.D. |
Chief Executive Officer, President and Director |
美元 715.00K |
24/02/2026 |
| Mr. Sandip S. Kapadia, C.P.A.,M.B.A. |
Chief Financial Officer, Principal Accounting Officer and Chief Administrative Officer |
美元 507.61K |
24/02/2026 |
| Mr. Kumar Budur |
Chief Medical Officer |
美元 555.15K |
04/04/2025 |
| Mr. Andrew Serafin |
Chief Strategy Officer |
美元 420.29K |
04/04/2025 |
| Mr. Adam Zaeske |
Executive Vice president and Chief Commercial officer |
-- |
24/03/2025 |
|
|
| Mr. Jeffrey S. Aronin |
Chairman of the Board |
24/02/2026 |
| Mr. R. Mark Graf |
Independent Director |
24/02/2026 |
| Mr. Gary L. Sender |
Independent Director |
24/02/2026 |
| Mr. Antonio J. Gracias |
Independent Director |
24/02/2026 |
| Dr. Andreas Wicki, PhD |
Independent Director |
24/02/2026 |
| Dr. Jeffrey M. Dayno, M.D. |
Chief Executive Officer, President and Director |
24/02/2026 |
| Ms. Linda M. Szyper |
Independent Director |
24/02/2026 |
| Mr. Juan A. Sabater |
Independent Director |
24/02/2026 |
| Mr. Ron Philip |
Independent Director |
24/02/2026 |
| Mr. Peter Anastasiou |
Independent Director |
24/02/2026 |
|
|
|
|
